Loading…

Novavax, Inc.NVAXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops and sells protein-based vaccines, including a COVID-19 vaccine and a combination flu/COVID pipeline.

Momentum weak 29
Mkt cap
$1.31B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$58.1M
20-day average traded
Fwd P/E
134.6×
forward earnings
ROIC−WACC
n/a
WACC 16.0%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$7.96
1D0.0%
1W-20.2%
1M-30.4%
3M-5.5%
6M-14.1%
YTD+18.4%
1Y+17.1%
ATR %9.7%
Beta2.13
52w lowhigh40.5% off high

What Novavax does

Develops and sells protein-based vaccines, including a COVID-19 vaccine and a combination flu/COVID pipeline.

Under a 2024 deal Sanofi now sells the COVID shot in most markets, so Novavax earns mainly milestone payments and royalties rather than its own product sales. Its Matrix-M adjuvant, an ingredient that strengthens the immune response, is also licensed into other makers' vaccines, including the R21 malaria vaccine. The company has cut costs sharply to match.

Products and services

  • Nuvaxovid/Novavax COVID-19 vaccine
  • Combination COVID/flu vaccine pipeline
  • Matrix-M adjuvant (licensed)

Customers

  • Governments/health systems
  • Sanofi (commercialization partner)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Protein-subunit vaccines

What could go right

  • Sanofi partnership royalties and milestones
  • Combination vaccine approval potential

What could go wrong

  • Declining COVID vaccine demand and market share
  • mRNA vaccine competitive dominance

Moat: narrow (IP / patents, regulatory licence). Proprietary Matrix-M adjuvant and protein-vaccine platform, but a distant also-ran versus mRNA COVID vaccine leaders.

Headquarters: Gaithersburg, Maryland, US · Founded: 1987 · Employees: 749

Named competitors

Novavax at a glance

Size Novavax (NVAX) is a United States Health Care company (Biotechnology) with a market value of $1.31B, the 2057th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.96 on 18 Nov 2026.

Performance Over six months the shares fell 14.1%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue fell 61.3% over the last twelve months (peer median +15.8%); the operating margin is -16.5% (peer median -178.1%).

Valuation It trades at 134.6× forward earnings against a peer median of 38.6× (2nd most expensive of 8).

Short interest Short interest is 28.1% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026NVAX 89Peer median 79
Six months, rebased to 100: Novavax against the median of its 20 peers (local-currency closes).

Novavax financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$412M$1.12B$682M$984M$1.98B
Revenue growth—+65%-31%-50%—
Gross profit$323M$1.05B$484M$704M$1.08B
EBITDA-$53.7M$591M-$183M-$374M-$616M
Net income-$76.7M$440M-$187M-$545M-$658M
Free cash flow-$244M-$250M-$100M-$771M-$505M
Capital expenditure$4.96M$6.39M$14.6M$58.8M$93.0M
Total debt$295M$278M$263M$281M$617M

Quarterly statements and history in the cockpit →

Novavax competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%TSHANUVBGENBTYRA61854588000403ANAB688739ABSIMLYS688105AKUMS688765NVAX6-month return →1-month return →
Up and to the right = strong over both horizons. Novavax is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×50×100×6185301207000403ANAB688739688105AKUMSNVAXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Novavax is the large dot.

Novavax competitors and peer comparison

Head to head with its named competitors (NVAX vs PFE vs MRNA vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Novavax NVAX$1.31B-14%-61%-17%134.6×n/a
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Moderna MRNA$79.6B+309%+13%-116%n/an/a
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%

How Novavax compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Novavax against its 20 peers (data as of 18 Nov 2026)
MeasureNVAXPeer medianRank in peer set
1-month return-30.4%-15.2%2nd lowest of 21
6-month return-14.1%-20.3%7th highest of 20
Distance from 52-week high-40.5%-48.1%8th highest of 21
Revenue growth (TTM)-61.3%+15.8%lowest of 18
Operating margin-16.5%-178.1%9th highest of 19
Forward P/E134.6×38.6×2nd most expensive of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%26.5×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%44.0×6.6%-7.0%
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%25.6×15.3%+9.9%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a

Questions

Who are Novavax's main competitors?
Named competitors: Pfizer/BioNTech (PFE), Moderna (MRNA), Sanofi (SAN.PA), GSK (GSK.L). The cockpit's measured peer set (industry) also includes Zhuhai Trinomab Pharmaceutical (688806.SS), Taysha Gene Therapies (TSHA), Nuvation Bio (NUVB), Generate Biomedicines (GENB), Tyra Bioscience (TYRA), CanSino Biologics (6185.HK).
Is Novavax expensive compared with its peers?
On forward p/e it trades at 134.6× against a peer median of 38.6×, 2nd most expensive of 8 in its peer set.
How has Novavax stock performed?
Over six months to 18 Nov 2026 the shares returned -14.1% against -20.3% for the median peer; over one year +17.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.